ASCO: Oncologists see benefit of medical marijuana, but not comfortable prescribing

IMAGE: Ashley Glode, PharmD, and colleagues show that despite perceived benefit, oncology providers not comfortable prescribing medical marijuana view more  Credit: University of Colorado Cancer Center A University of Colorado Cancer Center study presented at the American Society for Clinical Oncology (ASCO) Annual Meeting 2019 shows that while 73 percent of surveyed oncology providers believe that…

Details

Teens at greater risk of violence, injury during sexual assaults than previously thought

IMAGE: Adolescents may be at higher risk of physical violence and injury during sexual assaults than previously recognized, according to a new study co-written by Theodore P. Cross, a senior research… view more  Credit: Photo by L. Brian Stauffer CHAMPAIGN, Ill. — A recent study of the forensic evidence in 563 sexual assault cases in Massachusetts…

Details

ASCO 2019: 40-50 percent response rate for brigatinib after other next-gen ALK inhibitors

IMAGE: D. Ross Camidge, MD, PhD and the ATOMIC consortium show that brigatinib remains effective even after first-line therapy with another next-generation ALK inhibitor. view more  Credit: University of Colorado Cancer Center Crizotinib was the first drug licensed to treat ALK-positive non-small cell lung cancer (ALK+ NSCLC). Since then, a range of next-generation ALK-inhibitors including ceritinib,…

Details